May 13th 2024
Researchers at Massachusetts Eye and Ear led a phase 1/2 trial, which included 14 participants, that found the experimental treatment was safe and efficacious.
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
2nd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
May 18-19, 2024
Register Now!
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
(CME Credit) Virtual Case Studies™ in Cataract Surgery: Selecting Surgical Techniques and Preventing Intra-Operative Complications
View More
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
(CME Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
17th Annual Controversies in Modern Eye Care
View More
Thyroid Eye Disease: The Masquerading Eye Disorder—A Guide to Collaborative Care and Accurate Diagnosis
View More
(COPE Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(CME Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(COPE Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
The Ins and Outs of Lubricating Eye Drops
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Expert Perspectives in Diabetic Macular Edema – Considering Pathogenesis & Inflammation in Treatment Selection
View More
Community Practice Connections™: Novel Treatment Strategies in the Management of nAMD & DME - Lessons from Clinical Trial and Real-World Data
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (CME Credit)
View More
Medical Crossfire®: Expert Insights in Anti-VEGF Dosing for nAMD and DME – Optimizing Reduction in Treatment Burden
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (COPE Credit)
View More
EyeCon 2024
September 27-28, 2024
Register Now!
Heading to AAO? You’re invited to a CME dinner. Or join virtually!
Date TBA
Register Now!
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
Optic disc abnormality predictive of future visual-field loss
August 1st 2003Fort Lauderdale, FL-Both Heidelberg Retina Tomograph (HRT, Heidelberg Engineering) exams and stereoscopic optic disc photographs can show abnormalities that pre- dict glaucomatous visual-field abnormalities as early as 4 years before visual-field conversion occurs, according to results of an analysis conducted at the University of California San Diego, La Jolla.
Read More
Detection of glaucoma progression critical
August 1st 2003Fort Lauderdale, FL-What constitutes glaucoma progression and the relationship between progressive structural and functional injury? These were the main questions researchers set out to answer during a glaucoma mini-symposium at the annual meeting of the Association for Research in Vision and Ophthalmology.
Read More
Retinal thickness analyzer gives more precise information
June 1st 2003Dayton, OH-Move over a few disc diameters from the optic nerve head to assess the retinal thickness in the para-macular region for early diagnosis and close monitoring of the glaucomatous process. That's the message of Talia Technology Inc., Tampa.
Read More
Transition begins after Pfizer-Pharmacia merger
June 1st 2003New York-Pfizer Inc. will invest $400 million to expand its New Jersey facilities and potentially add 1,300 jobs, but plans to close five research and development sites around the world-including two in the United States- and other former Pharmacia Corp. offices as it begins the difficult logistical transition of its $57 billion takeover.
Read More
HLA-B27-associated anterior uveitis a common presentation
June 1st 2003Editor's Note: Anterior uveitis is the most common type of intraocular inflammation. Among patients with inflammation localized primarily to the anterior chamber, 50% or more are HLA-B27 positive. Inaddition, a number of these patients with HLA-B27-associated anterior uveitis have, or will develop, an associated systemicdisorder such as ankylosing spondylitis,reactive arthritis (formerly known asReiter's syndrome), inflammatory bowel disease, or psoriatic arthritis.
Read More
CA-The FDA approval of gatifloxacin ophthalmic solution 0.3% (Zymar, Allergan) marks a milestone as the first fourth-generation fluoroquinolone to enter the ophthalmic market. The therapy for the treatment of bacterial conjunctivitis caused by susceptible strains of bacteria also has a unique mechanism to prevent development of antibiotic resistance, according to Allergan.
Read More
IOL edge design directly affects ability to see at night
April 15th 2003Salt Lake City-Dysphotopsias, the unwant-ed optical images seen at night, pose an annoying and sometimes debilitating effect for cataract patients receiving IOLs with a truncated edge. To minimize these effects, efforts to modify the IOL edge have paid off, according to Randall J. Olson, MD.
Read More
OHTS identifies thinner corneas as risk for visual changes
April 1st 2003Omaha, NE-The Ocular Hypertension Treatment Study (OHTS) clearly demonstrat-ed that topical IOP-lowering medications can delay the onset of primary open-angle glaucoma. In addition, the OHTS study also revealed two very important secondary messages, which may be as important as the primary finding, according to M. Roy Wilson, MD.
Read More
Brimonidine may replace beta-blockers for older patients
November 15th 2002Tucson, AZ-Topical beta-blockers have been a mainstay of ongoing treatment for glaucoma for more than 20 years, but a new study adds to the evidence that they may not be the best option for long-term control of IOP for elderly patients.
Read More
Experts discuss implications of race on disease
November 15th 2002Editor's note: This is the second story in a three-part series covering a forum on "Ethnicity and Glaucoma" at Johns Hopkins University to commemorate the 20th anniversary of the Baltimore Eye Study. The meeting was sponsored by Johns Hopkins University School of Medicine and Ophthalmology Times and supported through an unrestricted educational grant from Alcon Laboratories Inc.
Read More
Clinicians take heed with new glaucoma procedures
November 15th 2002Los Angeles-Considering the limited availability of published randomized trials, glaucoma surgeons should remain skeptical about the safety and efficacy of viscocanalostomy and deep sclerectomy with collagen wick, said Donald S. Minckler, MD.
Read More
Estrogen exposure may protect women against cataract
September 15th 2002Fort Lauderdale, FL-Estrogen-whether endogenous or from hormone replacement therapy (HRT)-appears to help prevent cataract formation, according to Australian researcher Christine Younan, MD, who reported her findings at the annual meeting of the Association for Research in Vision and Ophthalmology.
Read More
Many still focus on controlling IOP, despite new definition
July 15th 2002New York-The official definition of glaucoma has changed over the years to downplay the role of IOP, although IOP does remain a central issue in the treatment and prevention of the condition. Such was the conclusion drawn from discussions at the Glaucoma 2002 meeting here.
Read More
NSAIDs may interfere with glaucoma medication
July 1st 2002San Antonio, TX-Before prescribing one of the newer medications for glaucoma, clinicians should ask what drugs the patient may be taking for aches and pains-especially non-steroidal anti-inflammatory agents (NSAIDs), including something as innocuous as aspirin, said William E. Sponsel, MD.
Read More
Various options available for correcting induced hyperopia
June 15th 2002Boston-The incidence of overcorrection following PRK and LASIK is fortunately very small, generally less than 5%. Unfortunately, the incidence of consecutive hyperopia after RK is significantly greater and, over time, becomes higher with a hyperopic shift, said Helen K. Wu, MD.
Read More
Molecule engineered to target neovascularization in AMD
June 1st 2002A genetically engineered molecule designed to kill cancers by destroying their rapidly growing blood vessels offers a new line of attack against age-related macular degeneration (AMD) and other retinal conditions, said Alan Garen, PhD.
Read More